Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 157 to 157 of 157 entries
Sorted by: Best Match Show Resources per page
Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States.

Infectious diseases and therapy

Goldstein M, Fergie J, Krilov LR.
PMID: 33656649
Infect Dis Ther. 2021 Mar;10:17-26. doi: 10.1007/s40121-020-00388-1. Epub 2021 Mar 03.

Despite being a leading cause of hospitalization due to lower respiratory tract infections, the treatment of respiratory syncytial virus (RSV) infection is primarily supportive. Palivizumab is the only licensed immunoprophylaxis (IP) available for preventing severe RSV infection in high-risk...

Cite
Goldstein M, Fergie J, Krilov LR. Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States. Infect Dis Ther. 2021;10:17-26doi: 10.1007/s40121-020-00388-1.
Goldstein, M., Fergie, J., & Krilov, L. R. (2021). Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States. Infectious diseases and therapy, 1017-26. https://doi.org/10.1007/s40121-020-00388-1
Goldstein, Mitchell, et al. "Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States." Infectious diseases and therapy vol. 10 (2021): 17-26. doi: https://doi.org/10.1007/s40121-020-00388-1
Goldstein M, Fergie J, Krilov LR. Impact of the 2014 American Academy of Pediatrics Policy on RSV Hospitalization in Preterm Infants in the United States. Infect Dis Ther. 2021 Mar;10:17-26. doi: 10.1007/s40121-020-00388-1. Epub 2021 Mar 03. PMID: 33656649; PMCID: PMC8017053.
Copy Download .nbib Format: NLM
Showing 157 to 157 of 157 entries